Baseline Characteristics of the VANISH Cohort.
暂无分享,去创建一个
Amit R. Patel | L. Mestroni | S. Solomon | S. Colan | M. Wheeler | J. McMurray | E. Braunwald | E. Orav | A. Pereira | R. Bach | H. Bundgaard | C. Canter | M. Russell | L. Benson | G. Lewis | C. Macrae | A. Owens | J. Jefferies | A. Cirino | Carolyn Y. Ho | S. Day | J. Rossano | R. Margossian | L. Choudhury | Kimberly Y. Lin | E. Pahl | K. Zahka | Matthew Taylor | H. Lever | A. Murphy | Allison L. Cirino | E. K. Hall | J. Becker | Amit R. Patel | A. Axelsson Raja | J. Vargas | S. Solomon | L. Shi | M. Taylor | A. C. Pereira | Jason R. Becker | Ling Shi | Jose D. Vargas | G. Lewis | S. Day | Renée Margossian
[1] B. Maron,et al. Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". , 2019, Circulation.
[2] E. Ashley,et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.
[3] N. Yamazaki,et al. Sunrise in melanoma management: Time to focus on melanoma burden in Asia , 2017, Asia-Pacific journal of clinical oncology.
[4] Akshay S. Desai,et al. The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial , 2017, American heart journal.
[5] Patrizio Lancellotti,et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[6] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[7] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[8] O. Havndrup,et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. , 2015, The lancet. Diabetes & endocrinology.
[9] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[10] F. Rutten,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[11] C. Delcayre,et al. AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP‐C null mice: role of FHL1 , 2014, Fundamental & clinical pharmacology.
[12] S. Abbara,et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. , 2013, JACC. Heart failure.
[13] C. Kramer,et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. , 2012, JACC. Cardiovascular imaging.
[14] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[15] Barry J Maron,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.
[16] Roger R Markwald,et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. , 2010, The Journal of clinical investigation.
[17] B. Byrne,et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. , 2010, Circulation.
[18] B. Cowan,et al. Left ventricular hypertrophy and renin-angiotensin system blockade , 2009, Current hypertension reports.
[19] M. Penicka,et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. , 2009, The Journal of molecular diagnostics : JMD.
[20] Heidi L Rehm,et al. Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.
[21] J. Seidman,et al. Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics , 2007, Journal of cardiovascular electrophysiology.
[22] K. Ohtomo,et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. , 2007, International heart journal.
[23] Phillip Ruiz,et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney , 2006, Proceedings of the National Academy of Sciences.
[24] C. Mady,et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.
[25] S. Seto,et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[26] S. Colan,et al. Theoretical and empirical derivation of cardiovascular allometric relationships in children. , 2005, Journal of applied physiology.
[27] B. Maron,et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). , 2004, American Journal of Cardiology.
[28] M. Entman,et al. Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy , 2004, Circulation.
[29] R. Hui,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.
[30] T. David. The American Association for Thoracic Surgery , 2003 .
[31] M. Entman,et al. Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[32] J. Gardin,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.